

TILL LÄKARE MED KOPIA TILL VERKSAMHETSCHEF VID ONKOLOGKLINIK

IPSEN and Bristol Myers Squibb would kindly like to invite you to a virtual meeting about:

nivolumab + cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1st line

This interactive virtual meeting will focus on the 9ER trial with the combination of nivolumab + cabozantinib for mRCC patients in first line. It will be chaired by Petri Bono from Finland and we are happy to share that Thomas Powles and Viktor Grünwald will walk us through the data and discuss the landscape.



Petri Bono, is the Chief Medical Officer and part of the executive management team of Terveystalo Finland, the largest healthcare service company in Finland. He is also adjunct professor at University of Helsinki. Prior to Terveystalo he was the Chief Medical Officer at Helsinki University Hospital District. In addition, Dr. Bono has held various other leadership positions within Helsinki University Hospital, including as the Director and Physician-in-Chief of the Comprehensive Cancer Center. Dr Bono's research has been focused in many areas of molecular and immunological oncology during the last two decades. Dr Bono has participated in numerous clinical trials including many early phase immuno-oncological trials and published >90 peer reviewed papers in international journals. Petri Bono is a member of European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), as well as many national societies.



Viktor Grünwald, MD, is a professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in Essen, Germany. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in GU cancers, soft tissue sarcomas, head and neck cancers, with an emphasis on the academic development and translational research of immunotherapies in these indications. Professor Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer and later professor for Haematology and Oncology at the same institution. He became professor for Interdisciplinary Genitourinary Oncology at the University Hospital Essen in 2018, thereby chairing the section for medical treatments of GU cancers. Professor Grünwald served at the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and was part of scientific committees of the European International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Haematology and Oncology (DGHO). He has chaired different working groups in academic organizations, such as the Central European Society of Anticancer Drug Research (CESAR) studies group, German Medical Oncology studies group (AIO) and German Cancer Society (DKG). His training activities include ESMO preceptorships and the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (MCCR).



Thomas Powles, MBBS, MRCP, MD, is a Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, which is one of the UK's largest Cancer Centres. He trained as an Oncologist at Imperial College. His MD thesis from the University of London was on mechanisms of resistance to systemic therapy in urology cancer. He has had a major role in the development biomarkers and new drug strategies in urology cancer. This includes multiple EMA and FDA approvals. He has led a number of clinical trials (including eleven randomised phase IIIs) and translational oncology projects that have appeared in the major journals. These are both university led and pharmaceutical company sponsored studies. His grant income over the last 5 years is over £6 million. He has over 300 peer review publications. This includes two first author NEM publications and 3 first author Nature/Nature medicine publications. He has presented data at plenary sessions at the major meetings including ASCO 2020 and was awarded the bladder cancer award at ASCO/GU in 2018. He has an active role on social media with over 50,000 listens to his podcasts and over 3000 followers on Twitter. He leads the ESMO guidelines for renal and bladder cancer and is the track chair for non-prostate GU cancer in 2021 (Paris). He has previously participated in the steering committee for the educational and scientific tracks for ESMO meetings; this includes co-chairing ESMO IO 2019-2021.



Date
October 12th, 2021



Time
15:30 – 17:15 CET



Link will be sent to you via
email the day before the meeting
– October 11th, 2021

Register for the meeting here by October 5th, 2021.

www.9ER.se

Agenda on next page →

Agenda

15:30 – 15:40

Introduction & opening remarks by Chairman

Petri Bono, MD, PhD, Terveystalo Finland

15:40 – 16:00

CheckMate 9ER – what does the data tell us?

Thomas Powles, MD, Barts Cancer Institute UK

16:00 – 16:20

Questions & Discussion led by Chairman and speakers

Petri Bono, MD, PhD, Terveystalo Finland

Thomas Powles, MD, Barts Cancer Institute UK

Viktor Grünwald, MD, University Hospital Essen, Germany

16:20 – 16:40

CheckMate 9ER – identification and management of treatment related adverse events

Viktor Grünwald, MD, University Hospital Essen, Germany

16:40 – 17:00

Questions & Discussion led by Chairman and speakers

Petri Bono, MD, PhD, Terveystalo Finland

Thomas Powles, MD, Barts Cancer Institute UK

Viktor Grünwald, MD, University Hospital Essen, Germany

17:00 – 17:15

Closing remarks by Chairman

Petri Bono, MD, PhD, Terveystalo Finland

The speakers will participate throughout the meeting and are available for interaction during both Q&A sessions where you as a participant will have the opportunity to ask questions via a "chat" function.

I samband med din anmälan för deltagande i mötet, samlar Bristol-Myers Squibb Aktiebolag ("BMS") in dina personuppgifter för att hantera ditt deltagande på mötet samt att utvärdera och förbättra våra aktiviteter. Genom att fylla i och underteckna formuläret medger du att dina personuppgifter får behandlas av BMS för ovan nämnda syften. Dina personuppgifter lagras inte längre än vad som är förenligt med gällande lagar och regler. Sådant medgivande omfattar även övriga företag inom den koncern BMS tillhör, vilket kan innebära att dina personuppgifter överförs till ett tredjeland i enlighet med våra Bindande företagsbestämmelser som du kan läsa här:

<https://www.bms.com/assets/bms/us/en-us/pdf/binding-corporate-rules.pdf>.

Medgivandet omfattar även överföring till noggrant utvalda leverantörer som BMS använder sig av i samband med möten. Du har rätt att återkalla ditt medgivande, invända mot eller begrän-

sa BMS behandling av dina personuppgifter, få information om vilka av dina personuppgifter vi behandlar, begära en kopia av dina personuppgifter, rätt att få personuppgifterna överförda till en annan personuppgiftsansvarig när det är tekniskt möjligt och få dem korrigerade eller raderade genom att kontakta BMS. Personuppgiftsansvarig: Bristol Myers Squibb Aktiebolag, organisationsnummer 556092-9886, Box 1172, 171 23 Solna. Du kan kontakta vårt dataskyddssombud för EU på EUDPO@BMS.com för att utöva de dataskyddsrättigheter du kan ha eller om du har funderingar eller frågor kring hur dina personuppgifter hanteras av BMS. Om du har klagomål kan du även vända dig till Datainspektionen i Sverige eller till tillsynsmyndigheten där du bor eller arbetar.

Bristol Myers Squibb står för arvode till föreläsare och IPSEN står för kostnad för teknisk plattform.

Med vänlig hälsning,

Alla vi på Bristol Myers Squibb som arbetar inom immunonkologi